title: [Proteus penneri].
abstract: Proteus penneri, formerly P. vulgaris biogroup 1, was recognized as a new species in 1982. This species is associated with clinical processes similar to those involving P. mirabilis and P. vulgaris and expresses similar pathogenic determinants. In clinical samples, P. penneri is mainly isolated from urine (50%), wound and soft tissue exudates (25%), and blood cultures (15%), mostly of nosocomial origin. Although P. penneri is easy to identify, it can be misidentified as P. vulgaris by automatic systems that do not include the indol test result in the identification process. This species has a characteristic susceptibility profile, essentially due to the production of the chromosomal inducible beta-lactamase HugA, which presents a high homology (86%) with CumA from P. vulgaris. HugA is inhibited by clavulanic acid and determines resistance to aminopenicillins and first- and second-generation cephalosporins, including cefuroxime, but does not affect cephamycins or carbapenems, and is inhibited by clavulanic acid. HugA is derepressed due to mutational processes in gene regulators, affecting the activity of cefotaxime and, to a much lesser extent, that of ceftazidime and aztreonam. This phenotype resembles the production of an extended spectrum beta-lactamase. Like other Proteus species, P. penneri is resistant to tetracyclines and should be considered resistant to nitrofurantoin.
authors.affiliation: Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, España. rcanton.hrc@salud.madrid.org
authors.forename: Rafael
authors.initials: R
authors.lastname: Cantón
authors.forename: M Paz
authors.initials: MP
authors.lastname: Sánchez-Moreno
authors.forename: María Isabel
authors.initials: MI
authors.lastname: Morosini Reilly
mesh_terms: D004352:Drug Resistance, Microbial; D006801:Humans; D011512:Proteus Infections / Q000453:epidemiology; D044095:Proteus penneri / Q000187:drug effects / Q000472:pathogenicity